Participated · Series A · Jul 2026

MID develops and manufactures space-grade electronic components and operates a consulting business for space product assurance, leveraging its Component Procurement & Provision Activity (CPPA) platform. The company localized a hermetically sealed ceramic-package 16Mbit SRAM designated as a ‘Space New Technology’ and installed on a technology validation satellite launched on the Nuri rocket. It is developing a non-hermetic epoxy-molding high-capacity NAND flash (128Gbit or more) intended for the ultra-small satellite DaejeonSat to be launched on the fifth Nuri mission. MID plans to build a 6,600-square-meter advanced packaging line in Daejeon and to scale mass-production processes for HTCC ceramic packages. The company reported revenue rising from about KRW 1.9 billion in 2021 to roughly KRW 12.4 billion last year and aims to expand into commercial and defense markets while establishing production for ceramic components used in semiconductor test equipment by 2029.

Participated · Seed · Jul 2026

Rosota develops next-generation surgical robots that embed AI trained on surgical data to understand and assist in real-time clinical situations. Its core asset is a proprietary data-collection infrastructure that captures surgical video, medical-device motion, and sensor data in real time, then anonymizes and integrates those signals for AI training. The company was spun out of the MediSC lab at Seoul National University Hospital and is led by CEO Seo Ye-chan with cofounders Choi Min-woo and Lee Dong-ho. Rosota positions itself to move beyond teleoperated robots by creating what it calls an "AI-native" surgical system that can learn and support surgeons’ decision-making. With the newly raised 1.5 billion won seed round, the company plans to further develop its data platform, train its AI models, and grow its clinical collaboration network. The team emphasizes a multidisciplinary approach combining clinical problem definition and robotic systems implementation.

Participated · Seed · Nov 2025

Cuckoo offers a corporate AI simultaneous interpretation service aimed at global sales, marketing, and customer-support teams. The platform delivers real-time translation and interpretation during business meetings and team calls, while continuously learning a customer’s internal documents and industry-specific terminology. It already supports 20+ languages and counts Snowflake, PagerDuty, and Weights & Biases among its early adopters. Founded by Lee Yong-hee and Kim Geon-woo, the company positions itself as a turnkey solution for enterprises seeking seamless cross-language collaboration. With fresh capital in hand, Cuckoo plans to accelerate product development, enhance its AI interpretation and localization capabilities, and pursue global expansion initiatives. The recent seed financing of $1.8 million provides its current financial footing; no additional revenue or user metrics were disclosed. The company operates under the legal entity Cuckoo Labs, Inc. from Seoul, South Korea.

Participated · Series B · Jul 2025

Illimis Therapeutics develops therapies for central nervous system and immune disorders using its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform. The company's lead program, ILM01 for Alzheimer's Disease, is entering preclinical development in the second half of 2025 with an IND targeted by the end of 2027. Proceeds from the recent financing will accelerate GAIA-based Alzheimer's programs, expand target indications into various immune disorders, and broaden its pipeline toward potential blockbuster candidates. Illimis is pursuing early-stage co-development with global pharmaceutical companies and research institutions and has established collaborations including Eli Lilly's Catalyze360-ExploR&D, participation in BMS Innovation Square Challenge, and membership in JLABS Singapore. A Scientific Advisory Board that includes Dr. Greg Lemke and Dr. Morgan Sheng provides strategic guidance across R&D, candidate discovery, and clinical trial design. The company was selected for the '2025 Global Joint Research to Defeat Dementia' and secured KRW 2.2 million ($1.6 million) in funding over three years to support international Alzheimer's research efforts.

Participated · Series A · Dec 2024

Munice develops Nightly, a sleep app that collects and analyzes biometric sleep data to produce personalized audio waves intended to guide users into deeper sleep states. The system combines signal processing and AI-driven personalization to detect individual sleep patterns and trigger tailored audio interventions in near real time. The company emphasizes a closed-loop approach that moves beyond passive tracking toward adaptive sleep coaching. Munice recently won the Asia-Pacific round of Deel's 'The Pitch', receiving $50,000 in seed funding and qualifying for the global finals in Paris where finalists may compete for additional investment. The startup faces typical scaling priorities cited in the competition context, including model stability, data pipeline robustness and data protection/compliance considerations. Success at the Paris final is expected to accelerate pilots, further funding and efforts to validate efficacy across larger user cohorts.